2.1. Study design and patients
mental illness, stroke, coronary atherosclerotic heart disease, hemophilia, liver or kidney disease
MALIGNANT TUMORS, STROKE, HEMOPHILIA
This non-randomized clinical controlled trial recruited adult patients infected with the Omicron variant of COVID-19 who were admitted to the designated hospital for treating COVID-19 in Shijiazhuang between November 5 and November 28, 2022. The inclusion criteria were: age between 18 and 50 years old; positive nucleic acid result; no previous systemic treatment; mild or moderate COVID-19 within 5 days of onset according to the “Diagnosis and Treatment Guide for COVID-19 (Version 9)”; and voluntary participation and signed written informed consent. Exclusion criteria were: patients with mental illness; participation in other clinical studies; patients with malignant tumors, hemophilia, severe liver or kidney disease, coronary atherosclerotic heart disease, stroke; or patients who were taking medications which were contraindicated for concomitant use with Paxlovid, including alfuzosin, amiodarone, eletriptan.This study was approved by the Institutional Review Board of the People Hospital of Shijiazhuang (No. 2023008) and conducted in accordance with the ethical principles for medical research involving human subjects established in the Helsinki Declaration, protecting the privacy and confidentiality of personal information of all participants. Written informed consent was obtained from each patient.